Consolidation with 90 Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up

• Published in: Leukemia & lymphoma Vol. 60; no. 11; pp. 2689 - 2696
• Main Authors: Jurczak, Wojciech, Gruszka, Alicja M, Sowa Staszczak, Anna, Dlugosz-Danecka, Monika, Szostek, Marta, Zimowska-Curylo, Dagmara, Giza, Agnieszka, Krawczyk, Katarzyna, Jakobczyk, Malgorzata, Hubalewska-Dydejczyk, Alicja, Szymczyk, Michal, Wróbel, Tomasz, Knopińska-Posłuszny, Wanda, Kisiel, Elżbieta, Skotnicki, Aleksander, Zinzani, Pier Luigi
• Format: Journal Article
• Language: English
• Published: United States 01.11.2019
• Subjects: ibritumomab tiuxetan; radioimmunotherapy; Mantle cell lymphoma
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428194.2019.1602261

Polish Lymphoma Research Group performed a phase-II trial to test whether Y ibritumomab tiuxetan radioimmunotherapy (Y90) may constitute an alternative consolidation for mantle cell lymphoma patients unfit for high-dose therapy. Forty-six patients were consolidated with Y90 following response to the 1st (  = 34) or 2nd line (  = 12) (immuno)chemotherapy. Majority of the patients had advanced disease (stage IV and presence of B-symptoms in 85% and 70%, respectively) and high MIPI (5.8, range 4-7). Consolidation with Y90 increased the complete remission (CR) rate obtained by the 1st line therapy from 41% to 91% and allowed for median PFS of 3.3 and OS of 6.5 years. In the first relapse, CR rate increased from 16% to 75%, while median PFS and OS totaled 2.2 and 6.5 years, respectively. At 8 years, 30% of patients, consolidated in the 1st line CR were alive, without relapse. Toxicity associated with Y90 is manageable, more severe after fludarabine-based regimens.